Evenity (Romosozumab) After Bariatric Surgery: Clinical Guide for Post-Bariatric Osteoporosis

Why Post-Bariatric Patients Represent a Distinct Osteoporosis Population

Bariatric surgery saves lives. Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) are associated with durable weight loss and resolution of type 2 diabetes, yet both procedures impose a sustained skeletal tax that standard osteoporosis protocols were not designed to address.

The Magnitude of Post-Bariatric Bone Loss

Bone mineral density (BMD) loss after RYGB is faster and more severe than in any other common clinical scenario outside of glucocorticoid therapy. A 2011 study in the Journal of Clinical Endocrinology and Metabolism (N=38) documented a mean hip BMD decline of 8.0% at 12 months post-RYGB, compared with 2.0% after SG 1. Ten-year observational data from the SOS (Swedish Obese Subjects) cohort showed that fracture rates in RYGB patients exceeded matched controls by 2.3-fold for all fractures and 3.1-fold for peripheral fractures 2.

These are not minor statistical signals. They represent real patients sustaining wrist, ankle, and hip fractures in their 50s and 60s.

Mechanisms Driving Bone Loss After Bariatric Surgery

Three overlapping processes accelerate skeletal deterioration after bariatric surgery:

1. Calcium and vitamin D malabsorption. RYGB bypasses the duodenum and proximal jejunum, the primary sites of active calcium transport. Even with supplementation at guideline-recommended doses (1,200 to 1,500 mg calcium citrate daily plus 3,000 IU vitamin D3), many patients maintain 25-hydroxyvitamin D (25-OH-D) below 30 ng/mL 3.

2. Secondary hyperparathyroidism (SHPT). Chronic calcium insufficiency drives PTH elevation, which accelerates cortical bone resorption. PTH greater than 65 pg/mL is found in roughly 40% of RYGB patients at two years post-op, even under standard supplementation regimens 4.

3. Unloading effect. Rapid weight loss removes mechanical loading stimulus from weight-bearing bone. Osteocyte mechanosensing declines, sclerostin secretion rises, and Wnt-mediated bone formation falls, a pathway that romosozumab directly targets.

Romosozumab's Mechanism of Action and Why It Fits Post-Bariatric Biology

Romosozumab is a humanized monoclonal antibody (IgG2) that binds sclerostin, a glycoprotein secreted primarily by osteocytes. Sclerostin inhibits the Wnt/β-catenin signaling cascade, suppressing osteoblast differentiation and activity. By neutralizing sclerostin, romosozumab simultaneously promotes bone formation (via Wnt activation) and suppresses bone resorption (via reduced RANKL expression), yielding a dual anabolic-antiresorptive effect seen with no other approved agent 5.

Why Sclerostin Inhibition Is Particularly Relevant After Weight Loss Surgery

After bariatric surgery and rapid weight loss, osteocyte sclerostin secretion rises as a physiological response to reduced mechanical loading 6. This means the very pathway romosozumab blocks is upregulated in the post-bariatric skeletal environment. Standard antiresorptives (bisphosphonates, denosumab) suppress resorption but do not counter the simultaneous suppression of bone formation driven by elevated sclerostin. Romosozumab addresses both sides of the imbalance.

Bone Formation Markers in the First 12 Months

P1NP (procollagen type I N-terminal propeptide), a bone formation marker, rises sharply within the first month of romosozumab treatment. In the FRAME trial (N=7,180), P1NP increased by approximately 145% above baseline at month 1, while CTX (C-telopeptide, a resorption marker) fell by 55% 7. In post-bariatric patients with elevated PTH and suppressed osteoblast activity, this rapid anabolic surge could theoretically rebuild trabecular and cortical bone faster than antiresorptive monotherapy.

Evidence Base: What the Major Trials Tell Us

No randomized controlled trial has enrolled exclusively post-bariatric patients for romosozumab. Clinicians must extrapolate from the three key studies while applying mechanistic reasoning specific to this population.

ARCH Trial (NEJM 2017)

The ARCH trial (N=4,093) compared 12 months of romosozumab 210 mg SC monthly followed by alendronate 70 mg weekly against alendronate alone for 24 months. At 24 months, the romosozumab-to-alendronate sequence produced a 48% reduction in new vertebral fractures (P<0.001), a 19% reduction in nonvertebral fractures, and a 27% reduction in hip fractures compared with alendronate alone 8. As the ARCH investigators wrote, "The reductions in fracture risk seen with the romosozumab-to-alendronate sequence were substantially larger than those seen with alendronate alone, supporting the use of an anabolic-first treatment strategy in patients at very high fracture risk." 8

The post-bariatric patient with T-score below -2.5 at the hip, prior fracture history, or SHPT fits the "very high fracture risk" profile described in ARCH.

FRAME Trial (NEJM 2016)

FRAME (N=7,180) tested romosozumab versus placebo for 12 months, then both groups transitioned to denosumab for 24 months. At 12 months, romosozumab cut new vertebral fracture risk by 73% versus placebo 7. The denosumab transition preserved and extended these gains. For post-bariatric patients who are not candidates for oral bisphosphonates due to GI concerns, a romosozumab-to-denosumab sequence may be preferable to the romosozumab-to-alendronate sequence used in ARCH.

STRUCTURE Trial (JBMR 2017)

STRUCTURE (N=436) enrolled patients previously treated with teriparatide and compared romosozumab versus alendronate. Romosozumab produced greater gains in total hip BMD (+2.6% vs. +0.6%) and femoral neck BMD 9. While this trial addressed a different prior-treatment context, it supports romosozumab's ability to build cortical hip bone, the site of highest fracture morbidity in post-bariatric patients.

Pre-Treatment Evaluation in the Post-Bariatric Patient

Before prescribing romosozumab to a bariatric surgery patient, clinicians must complete a structured pre-treatment assessment. Several steps are specific to the post-bariatric context and differ from the standard osteoporosis workup.

Mandatory Laboratory Panel

The FDA prescribing information for Evenity lists hypocalcemia as a contraindication 10. In post-bariatric patients, hypocalcemia is not rare, it is expected in undertreated patients. Obtain the following before the first injection:

• Serum calcium (albumin-corrected or ionized)
• 25-OH-D (target: 40 to 60 ng/mL before starting)
• Intact PTH
• 24-hour urine calcium (to detect absorptive hypocalciuria)
• Serum phosphorus and magnesium
• BMP with creatinine (eGFR; romosozumab is not studied in eGFR <30 mL/min/1.73 m²)

Correcting Deficiencies Before the First Dose

If 25-OH-D is below 30 ng/mL, load the patient with 50,000 IU ergocalciferol (vitamin D2) weekly for 8 to 12 weeks before initiating romosozumab 11. If albumin-corrected calcium is below 8.5 mg/dL, increase calcium citrate supplementation to 1,800 to 2,000 mg elemental calcium daily in divided doses and recheck in 4 to 6 weeks. Calcium carbonate is poorly absorbed in achlorhydric post-bariatric patients; calcium citrate is the appropriate formulation 12.

Cardiovascular Screening

The ARCH trial showed a numerically higher rate of serious cardiovascular events in the romosozumab arm (2.5% vs. 1.9% in the alendronate arm) 8. The FDA added a Black Box Warning: romosozumab is contraindicated in patients who have had a myocardial infarction or stroke within the preceding 12 months 10. Bariatric patients are typically younger, but metabolic syndrome history means cardiovascular risk factors are common. Screen for prior MI, stroke, TIA, and unstable angina before prescribing.

Dosing, Administration, and the 12-Month Ceiling

Romosozumab comes as two prefilled syringes of 105 mg/1.17 mL each, administered as two consecutive subcutaneous injections at the same visit, totaling 210 mg. Injections are given monthly for exactly 12 months, no more 10. The anabolic effect wanes substantially after 12 months even with continued dosing; the gain is front-loaded in the first two quarters of treatment.

Post-bariatric patients do not require dose adjustments based on weight. The approved dose of 210 mg monthly applies regardless of BMI or body weight at the time of treatment.

Injection sites rotate among the abdomen, thigh, and upper arm. There are no oral bioavailability concerns because the drug is administered subcutaneously, bypassing the GI malabsorption that complicates oral bisphosphonate therapy in RYGB patients entirely.

Calcium Supplementation Protocol During Romosozumab Therapy

Romosozumab's anabolic activity mineralizes new osteoid and transiently pulls calcium from the extracellular pool. In patients with intact calcium absorption, this transient demand is easily met. In post-bariatric patients with compromised absorption, the same demand can precipitate symptomatic hypocalcemia within days of the first injection 10.

Target Supplementation Levels During Treatment

The American Society for Metabolic and Bariatric Surgery (ASMBS) recommends the following supplementation targets for RYGB patients with concurrent bone-active therapy 13:

• Elemental calcium citrate: 1,500 to 2,000 mg daily in three to four divided doses
• Vitamin D3: 3,000 IU daily minimum; titrate to 25-OH-D of 40 to 60 ng/mL
• Magnesium glycinate or citrate: 200 to 400 mg daily (magnesium depletion impairs PTH secretion and worsens hypocalcemia)

Monitoring Schedule During the 12-Month Course

Check serum calcium and 25-OH-D at baseline, one month after the first injection, three months in, and then every three months through the full 12-month course. If serum calcium drops below 8.0 mg/dL at any point, hold the next romosozumab injection and recheck in two weeks after intensifying supplementation. Do not resume until calcium normalizes.

Transition Therapy After the 12th Romosozumab Dose

Discontinuing romosozumab without a transition antiresorptive causes rapid bone loss within 12 months, partly from a rebound increase in bone resorption markers 14. Planning the transition at the time of romosozumab initiation is not optional.

Antiresorptive Options in the Post-Bariatric Context

Denosumab 60 mg SC every 6 months is the preferred transition agent in most post-bariatric patients. It requires no GI absorption, avoids the esophageal irritation risk of oral bisphosphonates, and produced 8.3% lumbar spine BMD gains above placebo over 10 years in the FREEDOM extension 15. The main risk is rebound vertebral fractures if denosumab is ever discontinued without bridging to a bisphosphonate, so patients must commit to long-term therapy.

Zoledronic acid 5 mg IV annually is an appropriate option when IV access is available and cardiovascular risk does not preclude its use. IV administration bypasses GI malabsorption completely. The HORIZON-PFT trial (N=7,736) demonstrated a 70% reduction in morphometric vertebral fractures over 3 years with annual zoledronic acid 16.

Oral bisphosphonates (alendronate 70 mg weekly, risedronate 150 mg monthly) are the most affordable option but are complicated in post-bariatric patients by the following: altered gastric anatomy increases esophageal exposure time, achlorhydria may impair solubilization, and the requirement to remain upright for 30 to 60 minutes post-dose is impractical for patients with early dumping syndrome. Use oral bisphosphonates only when IV and SC options are inaccessible.

The Romosozumab-to-Denosumab-to-Zoledronic Acid Ladder

For post-bariatric patients with T-score below -3.0 at the hip or prior vertebral fracture, a three-step sequence produces the most durable protection:

1. Romosozumab 210 mg SC monthly for 12 months (anabolic phase; maximum BMD gain)
2. Denosumab 60 mg SC every 6 months for 4 to 6 years (consolidation phase)
3. Zoledronic acid 5 mg IV once or twice to consolidate denosumab gains before potential discontinuation

This sequence is not yet formally endorsed by a single society guideline but is consistent with the AACE/ACE Osteoporosis Clinical Practice Guidelines (2020), which state: "In patients at very high fracture risk, anabolic therapy should precede antiresorptive therapy." 17

Special Situations Unique to Post-Bariatric Patients

Concurrent Secondary Hyperparathyroidism

If intact PTH remains above 100 pg/mL despite calcium and vitamin D optimization, cinacalcet or parathyroidectomy consultation may be needed before romosozumab initiation. High PTH drives cortical bone resorption via a mechanism that partially overrides romosozumab's antiresorptive component. A 2020 analysis of the FRAME dataset found that patients with elevated PTH at baseline had attenuated hip BMD response compared with PTH-normal participants (mean hip BMD gain: 2.1% vs. 3.9%) 18.

Sleeve Gastrectomy vs. Roux-en-Y Gastric Bypass

Sleeve gastrectomy spares the duodenum, so calcium absorption, while reduced by achlorhydria and rapid gastric emptying, is less severely impaired than after RYGB. Post-SG patients may achieve adequate calcium sufficiency with 1,200 mg elemental calcium citrate daily plus 2,000 IU vitamin D3 19. Pre-treatment hypocalcemia is therefore less common after SG, but the workup remains mandatory.

Premenopausal Women After Bariatric Surgery

Romosozumab is FDA-approved only in postmenopausal women. Premenopausal women with post-bariatric osteoporosis are a distinct and underserved group. Off-label use of romosozumab in premenopausal women is not supported by controlled trial data. The Endocrine Society's 2019 clinical practice guideline on premenopausal osteoporosis recommends against anabolic therapy unless a woman has failed bisphosphonates and has a documented secondary cause of bone loss 20. Post-bariatric bone loss qualifies as a secondary cause, but the guideline does not specifically endorse romosozumab in this population.

Men After Bariatric Surgery

RYGB in men produces similar rates of hip BMD loss as in women. Romosozumab is not FDA-approved for use in men; the label specifies postmenopausal osteoporosis. A phase 3 trial in men (NCT01950364) showed BMD gains comparable to those seen in women, but regulatory approval for men has not been granted in the United States as of mid-2025. Prescribing romosozumab to post-bariatric men represents off-label use requiring informed consent and documented discussion.

Monitoring Bone Response During Treatment

BMD by dual-energy X-ray absorptiometry (DXA) at the lumbar spine and total hip at baseline and 12 months is the standard monitoring strategy. Romosozumab typically produces 13.3% lumbar spine BMD gain and 6.9% total hip BMD gain over 12 months in the FRAME trial population 7. Post-bariatric patients with concurrent SHPT may see attenuated responses, making repeat DXA at 12 months critical for treatment planning.

Bone turnover markers offer earlier feedback. P1NP should rise by at least 50% above baseline at month 1 if romosozumab is pharmacologically active. A flat or falling P1NP at month 1 raises the question of severe calcium or vitamin D deficiency limiting osteoblast response and warrants urgent laboratory reassessment 21.

Lateral thoracolumbar spine X-ray or vertebral fracture assessment (VFA) by DXA should be performed at baseline to document prevalent vertebral fractures. Post-bariatric patients often have unrecognized vertebral deformities discovered incidentally on imaging performed for other reasons 22.

Practical Prescribing Checklist for the Clinician

Before writing the first romosozumab prescription for a post-bariatric patient, confirm each of the following:

• No MI or stroke in the past 12 months (Black Box Warning)
• Serum calcium corrected to >8.5 mg/dL
• 25-OH-D >30 ng/mL (40 to 60 ng/mL preferred)
• PTH documented; severe SHPT addressed if PTH >100 pg/mL
• Calcium citrate supplementation plan in place (1,500 to 2,000 mg elemental daily)
• Vitamin D3 supplementation plan in place (>3,000 IU daily or titrated to level)
• Transition antiresorptive agent identified and discussed with patient
• DXA with VFA at baseline documented
• Informed consent including cardiovascular risk and off-label status (if applicable)

The Endocrine Society's 2019 osteoporosis guideline states: "Patients at very high fracture risk should be offered anabolic therapy as initial treatment rather than waiting for antiresorptive agents to fail." 23 Post-bariatric patients with hip T-score below -2.5 plus prior fracture or SHPT clearly meet that threshold.

At the 12-month mark, administer denosumab 60 mg SC no later than 4 weeks after the final romosozumab injection to prevent rebound bone loss and consolidate the structural gains achieved during the anabolic phase 14.